Editas IPO Will Test Investment Crispness For CRISPR Gene Editing
This article was originally published in Scrip
Executive Summary
By filing for an initial public offering on NASDAQ the genomics company Editas Medicine Inc. hopes to cash in on rising awareness of gene editing's power and the simplicity promised from the so-called CRISPR technique.